Johnson & Johnson

09/27/2024 | Press release | Distributed by Public on 09/27/2024 06:06

Novel combination of TALVEY® (talquetamab tgvs) and TECVAYLI® (teclistamab cqyv) suggests high response rates and durable responses in triple class refractory patients with[...]